Barr Joins Challenge To Zyprexa Patent

Law360 (December 3, 2004, 12:00 AM EST) -- Three years after Barr Laboratories Inc. successfully challenged the patent on Eli Lilly’s blockbuster antidepressant Prozac, the company has set its sights on the patent for Lilly’s new top-selling drug, the anti-psychotic Zyprexa.

Lilly has filed another patent infringement lawsuit Barr, the fourth generic maker to challenge the patent on the blockbuster anti-psychotic drug Zyprexa, Barr confirmed.

Lilly, already entrenched in litigation against three other challengers to the patent, filed its lawsuit on Wednesday in the U.S. District Court for the Southern District of Indiana to...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.